Dose of desferrioxamine and evolution of HIV-1 infection in thalassaemic patients
| Autor: | Mariane de Montalembert, Carlo Dessì, Dominique Costagliola, Sylvain Baruchel, Pierre Fondu, Jean-Jacques Lefrère, Markissia Karagiorga, Henri Perrimond, Robert Girot, Catherine Briand, Paolo Rebulla |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Splenectomy Human immunodeficiency virus (HIV) HIV Infections Deferoxamine medicine.disease_cause Gastroenterology Continuous variable Internal medicine medicine Humans Cumulative incidence Seroconversion Child Acquired Immunodeficiency Syndrome business.industry Proportional hazards model Confounding beta-Thalassemia Hematology Surgery Disease Progression HIV-1 Female Stage iv business Follow-Up Studies |
| Zdroj: | British journal of haematology. 87(4) |
| ISSN: | 0007-1048 |
| Popis: | Summary To study the relationship between the dose of desferrioxamine (DFX) and the progression of the HIV-1 disease in thalassaemia major patients (TMP), 64 seropositive TMP patients were studied. Cumulative incidence of CDC stage IV was calculated using a non-parametric life-table method. The association with the mean daily dose of DFX was tested with a Cox proportional hazards model which was also used to adjust for confounding variables. The median of the mean daily dose of DFX over the seropositive period was 40mg/kg (range 0-65mg/kg). Age at seroconversion (P < 0.02) and splenectomy (P < 0.03) were found to be associated with the mean daily dose of DFX. 6.5 years after seroconversion, 11% of those who had been prescribed more than 40mg/kg of DFX daily had entered stage IV versus 35% of those who had been prescribed a lower dose (P < 0.01). When the dose was taken as a continuous variable it was found that the rate of progression was significantly smaller in TMP receiving a higher dose (P < 0.002). even after adjusting for age and splenectomy (P < 0.02). Although it should be noted that these results were obtained in an observational study, possibly biased by a non-random allocation of the DFX dose, we believe that they are striking enough to support the claim that the role of DFX in the progression of HIV disease should be further evaluated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text